文献速递精神分裂症与精神病性障碍

重新评估精神分裂症抗精神病药物效应的异质性:一项meta分析

Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis.
PubMed 文献 · World Psychiatry · 2022-01-01

该研究利用个体患者数据(384例抗精神病药治疗,88例安慰剂)和66项临床试验(17202例患者)的study-level数据,估计安慰剂反应与药物特异性效应的相关性,并量化抗精神病药治疗效应的异质性。两种分析均发现PANSS总分上安慰剂反应与治疗效应呈负相关(ρ=-0.32, p=0.002;ρ=-0.39, p<0.001)。采用最保守估计的meta分析显示抗精神病药特异性效应存在显著个体间变异,最高四分位患者PANSS总分获益≥17.7分,而最低四分位患者相对安慰剂呈现不利效应。

要点

  • 个体患者数据与study-level数据均显示安慰剂反应与治疗效应负相关(ρ=-0.32和ρ=-0.39)。
  • 抗精神病药特异性效应存在显著个体间变异,最高四分位PANSS总分获益≥17.7分。
  • 最低四分位患者相对安慰剂呈现不利效应,支持个体化治疗的可能性。

核心结论

  • 抗精神病药治疗精神分裂症存在临床有意义的治疗效应异质性,提示个体化治疗有成功潜力。

研究设计与样本

  • 个体患者数据来自YODA数据库,包括384例接受抗精神病药治疗和88例接受安慰剂的患者。
  • study-level数据来自一项纳入66项临床试验、共17202例患者的meta分析。

主要发现

  • 个体患者数据分析显示安慰剂反应与治疗效应在PANSS总分上呈负相关(ρ=-0.32, p=0.002)。
  • study-level数据分析显示安慰剂反应与治疗效应在PANSS总分上呈负相关(ρ=-0.39, p<0.001)。
  • 采用最保守估计的meta分析显示抗精神病药特异性效应存在显著个体间变异。
  • 最高四分位患者PANSS总分获益≥17.7分,最低四分位患者相对安慰剂呈现不利效应。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is common experience for practising psychiatrists that individuals with schizophrenia vary markedly in their symptomatic response to antipsychotic medication. What is not clear, however, is whether this variation reflects variability of medication-specific effects (also called "treatment effect heterogeneity"), as opposed to variability of non-specific effects such as natural symptom fluctuation or placebo response. Previous meta-analyses found no evidence of treatment effect heterogeneity, suggesting that a "one size fits all" approach may be appropriate and that efforts at developing personalized treatment strategies for schizophrenia are unlikely to succeed. Recent advances indicate, however, that earlier approaches may have been unable to accurately quantify treatment effect heterogeneity due to their neglect of a key parameter: the correlation between placebo response and medication-specific effects. In the present paper, we address this shortcoming by using individual patient data and study-level data to estimate that correlation and quantitatively characterize antipsychotic treatment effect heterogeneity in schizophrenia. Individual patient data (on 384 individuals who were administered antipsychotic treatment and 88 who received placebo) were obtained from the Yale University Open Data Access (YODA) database. Study-level data were obtained from a meta-analysis of 66 clinical trials including 17,202 patients. Both individual patient and study-level analyses yielded a negative correlation between placebo response and treatment effect for the total score on the Positive and Negative Syndrome Scale (PANSS) (ρ=-0.32, p=0.002 and ρ=-0.39, p<0.001, respectively). Using the most conservative of these estimates, a meta-analysis of treatment effect heterogeneity provided evidence of a marked variability in antipsychotic-specific effects between individuals with schizophrenia, with the top quartile of patients experiencing beneficial treatment effects of 17.7 points or more on the PANSS total score, while the bottom quartile presented a detrimental effect of treatment relative to placebo. This evidence of clinically meaningful treatment effect heterogeneity suggests that efforts to personalize antipsychotic treatment of schizophrenia have potential for success.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. McCutcheon RA, Pillinger T, Efthimiou O, et al. Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis. World Psychiatry. 2022. PMID: 35524614. doi:10.1002/wps.20977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。